Show items per page
Elements: 42
Page 1 on 3
 TitleAuthors / EditorsDate
add to browser selection
Accounting for missing data caused by drug cessation in observational comparative effectiveness research: a simulation study Mongin, Denis; Lauper, Kim; Finckh, Axel; Frisell, Thomas; Courvoisier, Delphine 2022
add to browser selection
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement Nash, Peter; Kerschbaumer, Andreas; Dörner, Thomas; Dougados, Maxime; ... Smolen, Josef S 2021
add to browser selection
EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis Mankia, Kulveer; Siddle, Heidi J; Kerschbaumer, Andreas; Alpizar Rodriguez, Deshire; ... Emery, Paul 2021
add to browser selection
Personalized prediction of disease activity in patients with rheumatoid arthritis using an adaptive deep neural network Kalweit, Maria; Walker, Ulrich A.; Finckh, Axel; Müller, Rüdiger; ... Hügle, Thomas 2021
add to browser selection
Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort Ciurea, Adrian; Papagiannoulis, Eleftherios; Bürki, Kristina; von Loga, Isabell; ... Finckh, Axel 2021
add to browser selection
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors Kostine, Marie; Finckh, Axel; Bingham, Clifton O; Visser, Karen; ... Schaeverbeke, Thierry 2021
add to browser selection
Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatology Lauper, Kim; Kedra, Joanna; de Wit, Maarten; Fautrel, Bruno; ... Courvoisier, Delphine 2021
add to browser selection
Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries Dejaco, Christian; Alunno, Alessia; Bijlsma, Johannes WJ; Boonen, Annelies; ... Buttgereit, Frank 2021
add to browser selection
EMerging EULAR NETwork (EMEUNET): a remarkable foundation for the future Alunno, Alessia; Rivellese, Felice; Lauper, Kim; Aletaha, Daniel; ... Sepriano, Alexandre 2021
add to browser selection
Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced Ritchlin, Christopher T; Helliwell, Philip S; Boehncke, Wolf-Henning; Soriano, Enrique R; ... Deodhar, Atul 2021
add to browser selection
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update Smolen, Josef S; Landewé, Robert B M; Bijlsma, Johannes W J; Burmester, Gerd R; ... van der Heijde, Désirée 2020
add to browser selection
Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase ii study Mease, Philip J; Gladman, Dafna D; Deodhar, Atul; McGonagle, Dennis G; ... Helliwell, Philip S 2020
add to browser selection
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research Kerschbaumer, Andreas; Smolen, Josef S; Nash, Peter; Doerner, Thomas; ... van der Heijde, Desirée 2020
add to browser selection
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial Deodhar, Atul; Helliwell, Philip S; Boehncke, Wolf-Henning; Kollmeier, Alexa P; ... Ritchlin, Christopher T 2020
add to browser selection
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update Gossec, Laure; Baraliakos, Xenofon; Kerschbaumer, Andreas; de Wit, Maarten; ... Smolen, Josef S 2020
add to browser selection
Evolving the comprehensive management of rheumatoid arthritis: identification of unmet needs and development of practical and educational tools Burmester, Gerd-Rüdiger; Álvaro-Gracia, José María; Betteridge, Neil; Calvo Alén, Jaime; ... van de Laar, Mart 2020
add to browser selection
Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes Gabay, Cem; Burmester, Gerd R; Strand, Vibeke; Msihid, Jérôme; ... Boyapati, Anita 2020
add to browser selection
Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial Burmester, Gerd R; Buttgereit, Frank; Bernasconi, Corrado; Álvaro-Gracia, Jose M; ... John, Markus R 2020
add to browser selection
Individual therapeutic DAS28-d crit responses differentiate between effectiveness of rheumatoid arthritis therapies and reflect patient-reported outcomes: retrospective analysis of DAS28 responses in comparative tocilizumab studies Koehm, Michaela; McIntosh, Matthew J; Hofmann, Michael W; Abraham, Varghese; ... Behrens, Frank 2020
add to browser selection
Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbidities Kvien, Tore K; Balsa, Alejandro; Betteridge, Neil; Buch, Maya H; ... Dougados, Maxime 2020
<< previous | 1 | 2 | 3 |